Literature DB >> 25232643

Functional gold nanoparticles as potent antimicrobial agents against multi-drug-resistant bacteria.

Xiaoning Li1, Sandra M Robinson, Akash Gupta, Krishnendu Saha, Ziwen Jiang, Daniel F Moyano, Ali Sahar, Margaret A Riley, Vincent M Rotello.   

Abstract

We present the use of functionalized gold nanoparticles (AuNPs) to combat multi-drug-resistant pathogenic bacteria. Tuning of the functional groups on the nanoparticle surface provided gold nanoparticles that were effective against both Gram-negative and Gram-positive uropathogens, including multi-drug-resistant pathogens. These AuNPs exhibited low toxicity to mammalian cells, and bacterial resistance was not observed after 20 generations. A strong structure-activity relationship was observed as a function of AuNP functionality, providing guidance to activity prediction and rational design of effective antimicrobial nanoparticles.

Entities:  

Keywords:  MDR E. coli; MRSA; antimicrobial agents; gold nanoparticles; mode of action; structure−activity relationship; uropathogens

Mesh:

Substances:

Year:  2014        PMID: 25232643      PMCID: PMC4212784          DOI: 10.1021/nn5042625

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


The emergence of multi-drug-resistant (MDR) bacteria has become a severe threat to public health.[1] According to a report published by the U.S. Centers for Disease Control and Prevention, antibiotic resistant bacteria cause millions of infections and thousands of deaths every year in the U.S.[2] Additionally, the significant and continuous decrease in the number of approved antibiotics in the past decade has contributed to the increasingly threatening situation[3] that has resulted in an urgent need for the discovery of novel antibacterials and treatment strategies.[4] There are a number of actively pursued strategies, including searching for new antimicrobials from natural products, modification of existing antibiotic classes, and the development of antimicrobial peptides.[5] Nanoparticles (NPs) provide versatile platforms for therapeutic applications based on their physical properties.[6−8] For example, NP size range is commensurate with biomolecular and bacterial cellular systems, providing additional interactions to small molecule antibiotics.[9,10] The high surface to volume ratio allows incorporation of abundant functional ligands, enabling multivalency on NP surface to enhance interactions to target bacteria. Utilizing these characteristic features, NPs have been conjugated with known antibiotics to combat MDR bacteria. The antibiotic molecules can be infused with NPs via noncovalent interactions[11,12] or incorporated on NPs via covalent bonds.[13,14] Both methods have been reported for enhanced activity against bacteria, showing decreased minimum inhibitory concentration (MIC) in comparison with use of free antibiotics.[15−17] The improved performance is proposed to result from polyvalent effect of concentrated antibiotics on the NP surface as well as enhanced internalization of antibiotics by NPs.[18] Yet the dependence on existing antibiotics in these approaches may not be able to delay the onset of acquired resistance. The functional ligands on NP surface can provide direct multivalent interactions to biological molecules, allowing NPs to be exploited as self-therapeutic agents.[19−21] This strategy can circumvent the employment and the potential limitation of existing antibiotics in nanocarrier systems.[22] For assembly of such self-therapeutic NPs, the essentially inert and nontoxic nature of gold makes it an attractive core material.[23] To this end, we synthesized a series of self-therapeutic gold nanoparticles (AuNPs) as an antimicrobial agent. The structure–activity relationship of the functional ligands on 2 nm core AuNP revealed that AuNP antimicrobial properties can be tailored through surface hydrophobicity, providing a new aspect to design antimicrobial nanomaterials. On the basis of these studies, we focused on the most potent AuNP candidate and tested this particle with clinically isolated uropathogens. The result showed inhibited growth of multiple strains of uropathogens, including many MDR strains and methicillin-resistant Staphylococcus aureus (MRSA). Significantly, this AuNP did not induce bacterial resistance even after 20 generations. These particles are also compatible with mammalian cells: the maximum hemolytic index of this AuNP is >50, and at the MIC against MRSA, the C10-AuNP treated mammalian cells maintained >80% viability.

Results and Discussion

We recently reported that 2 nm core cationic monolayer-protected AuNPs can interact with cell membrane of Gram-positive and Gram-negative bacteria, resulting in formation of distinct aggregation patterns and lysis of bacterial cell.[24] Similarly, Jiang and co-workers also demonstrated that blebbing caused by cationic AuNPs induced bacterial membrane damage.[20] These results suggested that 2 nm AuNPs with cationic surface properties could be used as antimicrobial agents. To systematically investigate the role of surface chemistry in NP antimicrobial efficacy, AuNPs were synthesized with a range of different cationic functionalities featuring different chain length, nonaromatic, and aromatic characteristics (Figure ). All AuNPs were highly soluble in water; including NP 3 with the most hydrophobic end group (stock solution concentration was 56 μM).
Figure 1

Molecular structures of functional ligands on AuNPs.

Molecular structures of functional ligands on AuNPs. We first evaluated the functional AuNP antimicrobial activities on a laboratory strain (Escherichia coli DH5α), using broth dilution methods to determine the minimal inhibitory concentrations (MICs).[25] AuNPs were incubated with 5 × 105 cfu/mL of E. coli overnight. All AuNPs were able to completely inhibit the proliferation of E. coli at nanomolar concentrations; the MICs of different AuNPs, however, varied by the R group. To correlate antimicrobial activity with AuNP surface functionality, we plotted the MICs against the calculated AuNP end group log P values that quantitatively represent the relative NP surface hydrophobicity (Figure ).[26] A marked structure–activity relationship was observed, with hydrophobic NPs being more effective against E. coli growth. The most hydrophobic AuNP tested, NP 3 that carried an n-decane end group was capable of inhibiting E. coli proliferation at only 32 nM.
Figure 2

MIC values (nM) of AuNPs bearing different hydrophobic surface ligands against laboratory E. coli DH5α. Log P represents the calculated hydrophobic values of the end groups.

MIC values (nM) of AuNPs bearing different hydrophobic surface ligands against laboratory E. coli DH5α. Log P represents the calculated hydrophobic values of the end groups. We next tested the antimicrobial activities of the most potent antimicrobial (NP 3) on uropathogenic E. coli clinical isolates (Table ). Five isolates with differing resistance to clinically used antibiotics (resistant to 1–17 drugs, depending on strain) were used for this study. NP 3 suppressed the growth of all five uropathogenic strains of E. coli, including three MDR at a concentration of 16 nM, lower[27] or similar to[20] reported antibiotic-capped AuNPs. The comparable MIC values of MDR and laboratory strains suggest that C10-AuNP could potentially address the common mechanisms of bacterial resistance.
Table 1

MIC Values of NP 3 against Uropathogens

strainspeciesMIC (nM)no. of resistant drugsMDR
CD-2E. coli161No
CD-496E. coli162Yes
CD-3E. coli163Yes
CD-19E. coli164Yes
CD-549E. coli1617Yes
CD-866E. cloacae complex162Yes
CD-1412E. cloacae complex84Yes
CD-1545E. cloacae complex167Yes
CD-1006P. aeruginosa161No
CD-23P. aeruginosa3213Yes
CD-1578S. aureus644Yes
CD-489S. aureus - MRSA3210Yes
Next, NP 3 was further tested with more species/strains of uropathogenic clinical isolates, including Gram-negative Enterobacter cloacae complex and Pseudomonas aeruginosa and Gram-positive S. aureus and methicillin-resistant S. aureus (MRSA) (Table ). Among these isolates, P. aeruginosa has intrinsic resistance to a variety of antibiotics due to their exceptionally low outer-membrane permeability and multidrug efflux pumps.[28] Likewise, S. aureus has been a stumbling block for antimicrobial treatment, overcoming most of the therapeutic chemo-agents developed in the past five decades.[29] Particularly, MRSA has emerged as “superbug”, resistant to most antibiotics commonly used for the staph infections.[30] NP 3 was effective in treating each of these pathogens, with MICs of 8–64 nM. On the basis of the enhanced toxicity of NP 3, we hypothesized that the cationic hydrophobic AuNPs are particularly effective at compromising the integrity of bacterial membrane, causing toxicity to bacterial cells.[24] To support this hypothesis, we employed a propidium iodide (PI) staining assay. PI can only penetrate bacterial cells with compromised membrane and binds nucleic acids, with a concomitant enhancement of red fluorescence.[31,32] Uropathogens, E. coli CD-2 and S. aureus CD-489, were chosen as representative Gram-negative and Gram-positive strains. Bacteria (1 × 108 cfu/mL) were incubated with NP 3 at a final concentration of 500 nM for 3 h at 37 °C and then stained with PI before imaging. Confocal laser scanning microscopy (CLSM) images in Figure showed NP-induced membrane damage in both bacteria.
Figure 3

PI staining showing NP 3 (C10-AuNP)-induced bacterial cell membrane damage. Scale bar is 5 μm.

PI staining showing NP 3 (C10-AuNP)-induced bacterial cell membrane damage. Scale bar is 5 μm. To study the development of bacterial resistance to NP 3, E. coli CD-2 was exposed to sub-MIC (66% of MIC) of NP 3, with the obtained bacterial cell population defined as the first generation. After harvesting the first generation, the MIC was tested and a second generation was generated by exposing the first generation at its sub-MIC (66%). After 20 generations, E. coli remained susceptible to the original MIC of 16 nM. Compared to literature reported rate at which E. coli acquires resistance to conventional antibiotics,[20] NP 3 significantly delayed evolution of resistance. This lack of bacterial adaptation provides a means of potentially controlling and preventing the drug resistance.[33,34] To assess the biocompatibility of our antimicrobial NP 3, we performed hemolysis assay on human red blood cells as well as viability assays on mammalian cells. At all the MIC concentrations tested (in the range of 4 nM to 128 nM), NP 3 showed modest hemolytic activity as shown in Figure . HC50, which is the concentration to lyse 50% of human red blood cells,[35] was ∼400 nM for NP 3. The hemolytic index (HC50/MIC) was used to assess NP 3 selectivity against eukaryotic cells; therefore, the maximum hemolytic index of NP 3 was 50 (400 nM/8 nM). Similarly, after treatment with NP 3 at 128 nM, NIH-3T3 fibroblast cells maintained a viability of 80% (see Supporting Information), indicating low toxicity against mammalian cells. The observed AuNP cell selectivity could be explained by the fact that the surface of bacterial cells are more negatively charged than mammalian cells,[36] therefore accounting for the better affinity toward multications in bacteria. Also, the presence of cholesterol in mammalian cell membranes helps to stabilize the membranes, making them less sensitive to destruction by antimicrobial AuNPs.[37] It should be noted that the mammalian cell culture model used in this study may not fully reflect the in vivo toxicity profile.
Figure 4

Hemolytic activity of NP 3 at different concentrations. HC50 was estimated to be ∼400 nM (as denoted by the red cross in figure).

Hemolytic activity of NP 3 at different concentrations. HC50 was estimated to be ∼400 nM (as denoted by the red cross in figure).

Conclusion

We report here an antimicrobial strategy using self-therapeutic AuNPs to combat MDR bacteria. Cationic and hydrophobic functionalized AuNPs effectively suppressed growth of 11 clinical MDR isolates, including both Gram-negative and Gram-positive bacteria. The NP ligand structure–activity relationship revealed that surface chemistry played an important role in AuNP antimicrobial properties, providing a design element for prediction and rational design of new antibiotic NPs. Considering the efficient antimicrobial effect on MDR bacteria, the high biocompatibility, and the slow development of resistance, cationic hydrophobic nanoparticles such as NP 3 offer a promising strategy for the long-term combating of (MDR) bacteria, a key issue in healthcare.

Materials and Methods

Materials

All the reagents/materials required for nanoparticle synthesis were purchased from Fisher Scientific, except for gold salt, which was obtained from Strem Chemicals, Inc. The organic solvents were from Pharmco-Aaper or Fisher Scientific and used as received except for dichloromethane that was distilled in the presence of calcium hydride. NIH-3T3 cells (ATCC CRL-1658) were purchased from ATCC. Dulbecco’s Modified Eagle’s Medium (DMEM) (DMEM; ATCC 30-2002) and fetal bovine serum (Fisher Scientific, SH3007103) were used in cell culture.

NP Synthesis

Cationic gold nanoparticles were synthesized and characterized as previously reported.[38,39] (See Supporting Information for synthesis and characterization.)

Determination of Antimicrobial Activities of Cationic Gold Nanoparticles

Bacteria were cultured in LB medium at 37 °C and 275 rpm until stationary phase. The cultures were then harvested by centrifugation and washed with 0.85% sodium chloride solution for three times. Concentrations of resuspended bacterial solution were determined by optical density measured at 600 nm. M9 medium was used to make dilutions of bacterial solution to a concentration of 1 × 106 cfu/mL. A volume of 50 μL of these solutions was added into a 96-well plate and mixed with 50 μL of NP solutions in M9, giving a final bacterial concentration of 5 × 105 cfu/mL. NPs concentration varied in half fold according to a standard protocol, ranging from 125 to 3.9 nM. A growth control group without NPs and a sterile control group with only growth medium were carried out at the same time. Cultures were performed in triplicates, and at least two independent experiments were repeated on different days. The MIC is defined as the lowest concentration of AuNP that inhibits visible growth as observed with the unaided eye.[25]

Propidium Iodide Staining Assay

E. coli CD-2 and MRSA CD-489 (1 × 108 cfu/mL) were incubated with 500 nM C10-AuNP in M9 at 37 37 °C and 275 rpm for 3 h. The bacteria solutions were then mixed with PI (2 μM) and incubated for 30 min in dark. Five microliters of the samples was placed on a glass slide with a glass coverslip and observed with a confocal laser scanning microscopy, Zeiss 510 (Carl Zeiss, Jena, Germany) using a 543 nm excitation wavelength.

Resistance Development

E. coli CD-2 was inoculated in M9 medium with 10.4 nM (2/3 of 15.6 nM, MIC) at at 37 °C and 275 rpm for 16 h. The culture was then harvested and tested for MIC as describe above. E. coli CD-2 was cultured without NP as well every time as a control for comparison of MICs.

Hemolysis Assay

Hemolysis assay was performed on human red blood cells as we described in a previous study.[40] Briefly, citrate-stabilized human whole blood (pooled, mixed gender) was purchased from Bioreclamation LLC, Westbury, NY. The red blood cells were purified and resuspended in 10 mL of phosphate buffered saline as soon as received. A total of 0.1 mL of RBC solution was added to 0.4 mL of NP solution in PBS in 1.5 mL centrifuge tube. The mixture was incubated at 37 °C, 150 rpm for 30 min followed by centrifugation at 4000 rpm for 5 min. The absorbance value of the supernatant was measured at 570 nm with absorbance at 655 nm as a reference. RBCs incubated with PBS as well as water were used as negative and positive control, respectively. All samples were prepared in triplicate. The percent hemolysis was calculated using the following formula:

Mammalian Cell Viability Assay

A total of 20 000 NIH 3T3 (ATCC CRL-1658) cells were cultured in Dulbecco’s modified Eagle medium (DMEM; ATCC 30-2002) with 10% bovine calf serum and 1% antibiotics at 37 °C in a humidified atmosphere of 5% CO2 for 48 h. Old media was removed and cells were washed one time with phosphate-buffered saline (PBS) before addition of NPs in the prewarmed 10% serum containing media. Cells were incubated for 24 h at 37 °C under a humidified atmosphere of 5% CO2. Cell viability was determined using Alamar blue assay according to the manufacturer’s protocol (Invitrogen Biosource). After a wash step with PBS three times, cells were treated with 220 μL of 10% alamar blue in serum containing media and incubated at 37 °C under a humidified atmosphere of 5% CO2 for 3 h. After incubation, 200 μL of solution from each wells was transferred in a 96-well black microplate. Red fluorescence, resulting from the reduction of Alamar blue solution, was quantified (excitation/emission: 560 nm/590 nm) on a SpectroMax M5 microplate reader (Molecular Device) to determine the cellular viability. Cells without any NPs were considered as 100% viable. Each experiment was performed in triplicate.
  31 in total

1.  Trends in antimicrobial drug development: implications for the future.

Authors:  Brad Spellberg; John H Powers; Eric P Brass; Loren G Miller; John E Edwards
Journal:  Clin Infect Dis       Date:  2004-04-14       Impact factor: 9.079

Review 2.  The crisis in antibiotic resistance.

Authors:  H C Neu
Journal:  Science       Date:  1992-08-21       Impact factor: 47.728

3.  Aggregation and interaction of cationic nanoparticles on bacterial surfaces.

Authors:  Steven C Hayden; Gengxiang Zhao; Krishnendu Saha; Ronnie L Phillips; Xiaoning Li; Oscar R Miranda; Vincent M Rotello; Mostafa A El-Sayed; Ingeborg Schmidt-Krey; Uwe H F Bunz
Journal:  J Am Chem Soc       Date:  2012-04-17       Impact factor: 15.419

Review 4.  Molecular mechanisms of antibacterial multidrug resistance.

Authors:  Michael N Alekshun; Stuart B Levy
Journal:  Cell       Date:  2007-03-23       Impact factor: 41.582

5.  Tailored silica-antibiotic nanoparticles: overcoming bacterial resistance with low cytotoxicity.

Authors:  Larissa Brentano Capeletti; Luciane França de Oliveira; Kaliandra de Almeida Gonçalves; Jessica Fernanda Affonso de Oliveira; Ângela Saito; Jörg Kobarg; João Henrique Zimnoch dos Santos; Mateus Borba Cardoso
Journal:  Langmuir       Date:  2014-06-18       Impact factor: 3.882

Review 6.  The emergence and evolution of methicillin-resistant Staphylococcus aureus.

Authors:  K Hiramatsu; L Cui; M Kuroda; T Ito
Journal:  Trends Microbiol       Date:  2001-10       Impact factor: 17.079

7.  Invasive methicillin-resistant Staphylococcus aureus infections in the United States.

Authors:  R Monina Klevens; Melissa A Morrison; Joelle Nadle; Susan Petit; Ken Gershman; Susan Ray; Lee H Harrison; Ruth Lynfield; Ghinwa Dumyati; John M Townes; Allen S Craig; Elizabeth R Zell; Gregory E Fosheim; Linda K McDougal; Roberta B Carey; Scott K Fridkin
Journal:  JAMA       Date:  2007-10-17       Impact factor: 56.272

Review 8.  Nanocarriers as an emerging platform for cancer therapy.

Authors:  Dan Peer; Jeffrey M Karp; Seungpyo Hong; Omid C Farokhzad; Rimona Margalit; Robert Langer
Journal:  Nat Nanotechnol       Date:  2007-12       Impact factor: 39.213

Review 9.  Nanoparticle therapeutics: an emerging treatment modality for cancer.

Authors:  Mark E Davis; Zhuo Georgia Chen; Dong M Shin
Journal:  Nat Rev Drug Discov       Date:  2008-09       Impact factor: 84.694

Review 10.  Combating multidrug-resistant bacteria: current strategies for the discovery of novel antibacterials.

Authors:  Kieron M G O'Connell; James T Hodgkinson; Hannah F Sore; Martin Welch; George P C Salmond; David R Spring
Journal:  Angew Chem Int Ed Engl       Date:  2013-09-05       Impact factor: 15.336

View more
  108 in total

1.  Probing the Mechanism of LAL-32, a Gold Nanoparticle-Based Antibiotic Discovered through Small Molecule Variable Ligand Display.

Authors:  Rose Byrne-Nash; Danielle M Lucero; Niki A Osbaugh; Roberta J Melander; Christian Melander; Daniel L Feldheim
Journal:  Bioconjug Chem       Date:  2017-06-27       Impact factor: 4.774

2.  Electrochemical nanoparticle-enzyme sensors for screening bacterial contamination in drinking water.

Authors:  Juhong Chen; Ziwen Jiang; Jonathan D Ackerman; Mahdieh Yazdani; Singyuk Hou; Sam R Nugen; Vincent M Rotello
Journal:  Analyst       Date:  2015-08-07       Impact factor: 4.616

3.  Sensing by Smell: Nanoparticle-Enzyme Sensors for Rapid and Sensitive Detection of Bacteria with Olfactory Output.

Authors:  Bradley Duncan; Ngoc D B Le; Colleen Alexander; Akash Gupta; Gulen Yesilbag Tonga; Mahdieh Yazdani; Ryan F Landis; Li-Sheng Wang; Bo Yan; Serdar Burmaoglu; Xiaoning Li; Vincent M Rotello
Journal:  ACS Nano       Date:  2017-04-26       Impact factor: 15.881

4.  Flavonoid-Decorated Nano-gold for Antimicrobial Therapy Against Gram-negative Bacteria Escherichia coli.

Authors:  Suvadra Das; Tanay Pramanik; Megha Jethwa; Partha Roy
Journal:  Appl Biochem Biotechnol       Date:  2021-03-13       Impact factor: 2.926

5.  Nanoparticle probes for quantifying supramolecular determinants of biosurface affinity.

Authors:  N D B Le; S Hou; G Y Tonga; H A Jerri; S G Elci; T Mizuhara; V Normand; D Benczédi; R W Vachet; V M Rotello
Journal:  Part Part Syst Charact       Date:  2017-07-25       Impact factor: 3.310

6.  Silver nanoparticle conjugation affects antiacanthamoebic activities of amphotericin B, nystatin, and fluconazole.

Authors:  Ayaz Anwar; Ruqaiyyah Siddiqui; Muhammad Asim Hussain; Dania Ahmed; Muhammad Raza Shah; Naveed Ahmed Khan
Journal:  Parasitol Res       Date:  2017-12-07       Impact factor: 2.289

Review 7.  Cure of tuberculosis using nanotechnology: An overview.

Authors:  Rout George Kerry; Sushanto Gouda; Bikram Sil; Gitishree Das; Han-Seung Shin; Gajanan Ghodake; Jayanta Kumar Patra
Journal:  J Microbiol       Date:  2018-05-02       Impact factor: 3.422

Review 8.  Development of coinage metal nanoclusters as antimicrobials to combat bacterial infections.

Authors:  Dan Li; Beena Kumari; Jessa Marie Makabenta; Bailong Tao; Kun Qian; Xifan Mei; Vincent M Rotello
Journal:  J Mater Chem B       Date:  2020-10-28       Impact factor: 6.331

9.  Nanomaterials for the Treatment of Bacterial Biofilms.

Authors:  Li-Sheng Wang; Akash Gupta; Vincent M Rotello
Journal:  ACS Infect Dis       Date:  2015-10-21       Impact factor: 5.084

10.  Fully Zwitterionic Nanoparticle Antimicrobial Agents through Tuning of Core Size and Ligand Structure.

Authors:  Shuaidong Huo; Ying Jiang; Akash Gupta; Ziwen Jiang; Ryan F Landis; Singyuk Hou; Xing-Jie Liang; Vincent M Rotello
Journal:  ACS Nano       Date:  2016-09-16       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.